scholarly article | Q13442814 |
P356 | DOI | 10.1002/ART.1780250602 |
P698 | PubMed publication ID | 7046757 |
P50 | author | Ellen M Ginzler | Q91640182 |
P2093 | author name string | B H Hahn | |
T A Medsger | |||
G Ziegler | |||
N M Hadler | |||
M Weiner | |||
D A Albert | |||
J H Klippel | |||
M Schlesinger | |||
E V Hess | |||
J F Fries | |||
E V Barnett | |||
S Rosner | |||
C Wasner | |||
H S Diamond | |||
A Grayzel | |||
D Worth | |||
G Spencer-Green | |||
P433 | issue | 6 | |
P921 | main subject | systemic lupus erythematosus | Q1485 |
P304 | page(s) | 612-617 | |
P577 | publication date | 1982-06-01 | |
P1433 | published in | Arthritis and Rheumatism | Q23929027 |
P1476 | title | A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death | |
P478 | volume | 25 |
Q50988300 | "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. |
Q48494584 | A case of diffuse lupus encephalopathy successfully treated with high-dose intravenous methylprednisolone |
Q73635053 | Acute abdomen in systemic lupus erythematosus: the importance of early laparotomy |
Q50603809 | An epidemiologic analysis of end-stage lupus nephritis. |
Q37765837 | Analysis of clinical manifestations and pathology of lupus nephritis: a retrospective review of 82 cases |
Q35552703 | Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy |
Q71691168 | Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study |
Q40409570 | Aortic aneurysms in patients with autoimmune disorders treated with corticosteroids |
Q71959681 | Aspergillosis in systemic lupus erythematosus |
Q41260413 | Assessment of lupus: where are we now? |
Q74198328 | Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus |
Q34504806 | Atherosclerosis and connective tissue diseases |
Q72155864 | Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate |
Q34108825 | Circulating endothelial cells and vascular injury in systemic lupus erythematosus |
Q33561226 | Clinical and autoantibody correlations in Orientals with systemic lupus erythematosus |
Q71103145 | Clinical features and outcome of infection in systemic lupus erythematosus |
Q40154586 | Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases |
Q35031666 | Concurrent presentation of cryptococcal meningoencephalitis and systemic lupus erythematosus |
Q44081617 | Course and prognostic value of Systemic Lupus Erythematosus Disease Activity Index in black Caribbean patients |
Q37949332 | Current treatment recommendations for lupus nephritis |
Q40919356 | Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients |
Q36844749 | Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1. |
Q77746580 | Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature |
Q73203789 | Echocardiographic findings, lipids and lipoprotein(a) in patients with systemic lupus erythematosus |
Q72315249 | Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine lupus mice |
Q40868199 | End-stage renal disease in systemic lupus erythematosus |
Q34072179 | Endothelial dysfunction in chronic inflammatory diseases |
Q22299248 | Epidemiology and socioeconomic impact of skin disease in lupus erythematosus |
Q44112212 | Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study |
Q43532820 | Familial clustering of end-stage renal disease in blacks with lupus nephritis |
Q90697238 | From Severe Herpes Zoster to Rare Suid Herpesvirus Encephalitis: A New Twist of the Varicellovirus Genus Infection in Patients with Kidney Diseases |
Q74600355 | Infection in systemic lupus erythematosus |
Q36691113 | Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review |
Q71475036 | Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India |
Q35084903 | Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis |
Q34990100 | Infections in the immunocompromised rheumatologic patient |
Q41475106 | Infectious complications of immunosuppressive therapy in patients with rheumatic diseases |
Q74033013 | Innate immune mechanisms in the pathogenesis of systemic lupus erythematosus (SLE) |
Q37361762 | Intracellular demonstration of active TGFbeta1 in B cells and plasma cells of autoimmune mice. IgG-bound TGFbeta1 suppresses neutrophil function and host defense against Staphylococcus aureus infection |
Q40440616 | Invasive aspergillosis in systemic lupus erythematosus |
Q36683387 | Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus |
Q68492553 | Lupus Carditis |
Q71984938 | Lupus Nephritis in Thailand: Clinicopathologic findings and outcome in 569 patients |
Q40665188 | Lupus nephritis in childhood and adolescence |
Q40742350 | Malignant histiocytosis as a fatal complication of systemic lupus erythematosus |
Q36577423 | Mechanisms of disease: atherosclerosis in autoimmune diseases |
Q50563149 | Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. |
Q35588087 | Mucormycosis in systemic lupus erythematosus |
Q35552164 | Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus |
Q39644827 | Neoplastic associations of rheumatic diseases and rheumatic manifestations of cancer. |
Q40469520 | Neuropsychiatric Manifestations of Systemic Lupus Erythematosus |
Q41377143 | Nocardiosis in systemic lupus erythematosus. |
Q69791000 | Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus |
Q33561735 | Outcome and survival in systemic lupus erythematosus |
Q35551526 | Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades |
Q33567599 | Outcome of patients with systemic rheumatic disease admitted to medical intensive care units |
Q33448450 | Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort |
Q73251573 | Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus |
Q57704421 | Prevalence and significance of hypertension in systemic lupus erythematosus |
Q77798512 | Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus |
Q33286668 | Prognostic factors in systemic lupus erythematosus |
Q43051274 | Prophylactic use of antibiotics and immunisations in patients with SLE. |
Q35637257 | Raised serum S100B protein levels in neuropsychiatric lupus. |
Q35626485 | Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? |
Q35547805 | Renal haemodynamic characteristics in patients with lupus nephritis |
Q49216020 | Risk of infection in hospitalised children with systemic lupus erythematosus: a 10-year follow-up |
Q36307414 | Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study |
Q42942667 | Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice |
Q34564739 | Spontaneous immunoglobulin A secretion and lack of mitogen-responsive B cells in systemic lupus erythematosus |
Q50885213 | Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. |
Q47889345 | Survival of patients with SLE admitted to an intensive care unit-a retrospective study |
Q71581580 | Systemic lupus erythematosus |
Q43419630 | Systemic lupus erythematosus and cardiovascular disease |
Q41523547 | Systemic lupus erythematosus and multiple myeloma: a rare association |
Q39756290 | Systemic lupus erythematosus clinical issues |
Q33357929 | Systemic lupus erythematosus in Tunisia. A multicentric study. About 295 cases |
Q70287507 | Systemic lupus erythematosus in patients with chronic renal failure |
Q68918938 | Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity |
Q34034374 | Systemic lupus erythematosus in the elderly. |
Q34990070 | Systemic lupus erythematosus in the intensive care unit |
Q75828790 | Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity |
Q33555951 | Systemic lupus erythematosus without clinical renal abnormalities: renal biopsy findings and clinical course |
Q33562068 | Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. |
Q89835229 | The Urinary Exosomal miRNA Expression Profile is Predictive of Clinical Response in Lupus Nephritis |
Q67857724 | The actual survival rate in systemic lupus erythematosus: study of a 1976 cohort |
Q33535433 | The heart in systemic lupus erythematosus |
Q40179650 | The natural history of lupus erythematosus |
Q34484053 | Why do patients with lupus nephritis die? |
Q81772558 | [Accelerated atherosclerosis in rheumatic systemic diseases as an example of systemic lupus erythematosus--what is the consequence?] |
Q84600749 | [Comorbidity of systemic lupus erythematosus] |
Q69514089 | [Coronary trunk involvement in systemic lupus erythematosus. Possible role of corticotherapy. Apropos of a case] |
Q84600784 | [Infections in the immunocompromised host. What is the role of the medications?] |
Q77114590 | [Lupus nephropathy: implications of a long course] |
Q40699216 | n-3 fatty acids and renal diseases |
Search more.